The National Institutes of Health has begun early-stage clinical trials of an investigational coronavirus vaccine from Moderna intended to protect against a strain of the virus first discovered in South Africa.

The phase one trial is led and funded by the National Institute of Allergy and Infectious Diseases (NIAID). The trial will enroll approximately 210 healthy adult volunteers at four clinical research sites across the country, in the Atlanta, Cincinnati, Nashville and Seattle areas.

Join BJL on WhatsApp Status: Click here to Join BJL status for engagements, births, deals, levayos, events & more

Join BJL on WhatsApp Groups: Click here to Join an official BJL WhatsApp group for breaking news as it happens

According to the agency, the trial will enroll about 60 people ages 18 years and older who already received Moderna’s coronavirus vaccine from last year’s phase one trials, as well as about 150 others ages 18 through 55 years who have not received any COVID-19 vaccine.

Read more at The Hill.